Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside

Analyst Andres Y. Maldonado of H.C. Wainwright reiterated a Buy rating on Immunome, retaining the price target of $40.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors tied to Immunome’s advancing precision-oncology platform and multiple value-driving assets. He views varegacestat as the core of the story, supported by robust RINGSIDE Phase 3 data in adult desmoid tumors, alignment with regulators, and a regulatory path that includes an NDA already filed in the U.S. and an MAA filing in Europe expected by year-end 2026, all of which support a strong launch profile.

At the same time, he sees meaningful upside from the broader pipeline, particularly the newly initiated Phase 1 program for IM-3050, a FAP-targeting radioligand therapy designed to address historical limitations in this class and potentially serve as a pipeline-in-a-product if early results are positive. He also highlights the continued maturation of the ADC franchise, including ongoing development of IM-1021 and upcoming trials for additional TOP1 inhibitor–based ADCs, which together underscore sustained innovation and expansion potential; reflecting this, he reiterates a Buy rating and leaves his $40 price target unchanged.

Y. Maldonado covers the Healthcare sector, focusing on stocks such as ImmunityBio, Verastem, and CG Oncology, Inc.. According to TipRanks, Y. Maldonado has an average return of 42.1% and a 55.08% success rate on recommended stocks.